The urgent need to recover MHC class I in cancers for effective immunotherapy Garrido Torres-Puchol, Federico Aptsiauri, Natalia Doorduijn, Elien M. García Lora, Ángel Miguel van Hall, Thorbald We would like to thank Dr M Bernal who has helped us in preparing the figure for the manuscript. This work was supported by grants co-financed by FEDER funds (EU) from the Instituto de Salud Carlos III (CP03/0111, PI12/02031, PI 08/1265, PI 11/01022, PI11/01386, PI14/01978, PI15/00528, RETIC RD 06/020, RD09/0076/00165, PT13/0010/0039), Junta de Andalucia in Spain (Group CTS-143, and CTS-695, CTS-3952, CVI-4740 and PI 09/0382 grant), Worldwide Cancer Research 15-1166 grant, and by Dutch Cancer Society (UL 2010-4785, TvH). Immune escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class I expression, are commonly found in malignant cells. Tumor immune escape has proven to have a negative effect on the clinical outcome of cancer immunotherapy, including treatment with antibodies blocking immune checkpoint molecules. Hence, there is an urgent need to develop novel approaches to overcome tumor immune evasion. MHC class I antigen presentation is often affected in human cancers and the capacity to induce upregulation of MHC class I cell surface expression is a critical step in the induction of tumor rejection. This review focuses on characterization of rejection, escape, and dormant profiles of tumors and its microenvironment with a special emphasis on the tumor MHC class I expression. We also discuss possible approaches to recover MHC class I expression on tumor cells harboring reversible/‘soft’ or irreversible/‘hard’ genetic lesions. Such MHC class I recovery approaches might well synergize with complementary forms of immunotherapy. 2020-07-14T08:08:29Z 2020-07-14T08:08:29Z 2016-01-18 info:eu-repo/semantics/article Garrido, F., Aptsiauri, N., Doorduijn, E. M., Lora, A. M. G., & van Hall, T. (2016). The urgent need to recover MHC class I in cancers for effective immunotherapy. Current opinion in immunology, 39, 44-51. [http://dx.doi.org/10.1016/j.coi.2015.12.007] http://hdl.handle.net/10481/62960 10.1016/j.coi.2015.12.007 eng http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess Atribución-NoComercial-SinDerivadas 3.0 España Elsevier